Edoardo Mortato

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Efficacy and safety of mogamulizumab in Sézary syndrome with concomitant Crohn's disease.

Efficacy and safety of mogamulizumab in Sézary syndrome with concomitant Crohn's disease.

Journal: Dermatology reports

Published: February 01, 2026

Genetic profiling of patients with atopic dermatitis reveals immune and skin barrier variants associated with generalized eczema and optimal response to Dupilumab therapy.

Genetic profiling of patients with atopic dermatitis reveals immune and skin barrier variants associated with generalized eczema and optimal response to Dupilumab therapy.

Journal: Frontiers in immunology

Published: January 15, 2026

Long-Term Impact of Guselkumab on Systemic Inflammation Indices in Moderate-to-Severe Psoriasis.

Long-Term Impact of Guselkumab on Systemic Inflammation Indices in Moderate-to-Severe Psoriasis.

Journal: Journal of clinical medicine

Published: December 09, 2025

AVT04, a Biosimilar to Reference Product Ustekinumab, for the Treatment of Plaque Psoriasis: Insights from a Real-World Experience up to 28 Weeks.

AVT04, a Biosimilar to Reference Product Ustekinumab, for the Treatment of Plaque Psoriasis: Insights from a Real-World Experience up to 28 Weeks.

Journal: Dermatology and therapy

Published: December 01, 2025

Predictive Factors of Super-Responder Status to Dupilumab in Adult Atopic Dermatitis: A Real-World Monocentric Study.

Predictive Factors of Super-Responder Status to Dupilumab in Adult Atopic Dermatitis: A Real-World Monocentric Study.

Journal: International journal of dermatology

Published: November 20, 2025

Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study.

Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study.

Journal: Clinical and experimental dermatology

Published: October 21, 2025

Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?

Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?

Journal: The Journal of dermatological treatment

Published: June 09, 2025

Real-world effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis: a retrospective observational study with focus on head and neck involvement.

Real-world effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis: a retrospective observational study with focus on head and neck involvement.

Journal: Dermatology reports

Published: May 29, 2025

Could Disease Duration Influence Response to Dupilumab in Patients With Atopic Dermatitis? A Retrospective Real-Life Study.

Could Disease Duration Influence Response to Dupilumab in Patients With Atopic Dermatitis? A Retrospective Real-Life Study.

Journal: International journal of dermatology

Published: May 03, 2025

Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab.

Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab.

Journal: Dermatology reports

Published: April 23, 2025

Switching to brodalumab after failure of IL-17A inhibitors in psoriatic patients: A real-life multicentre study.

Switching to brodalumab after failure of IL-17A inhibitors in psoriatic patients: A real-life multicentre study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: April 22, 2025

Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study.

Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study.

Journal: Psoriasis (Auckland, N.Z.)

Published: April 08, 2025

Showing 1-12 of 35

Last Updated: 09/26/2026